Metraipolis › archive › dc_ca63bf37cb38

Tislelizumab-induced myositis antibody-negative myasthenia gravis in patients with urothelial carcinoma: a case report — Europe PMC PMID:42459703

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42459703
DOI: 10.3389/fimmu.2026.1854332
License (as archived): solo-consultazione
Archived: 2026-10-18T13:43:27.837Z
SHA-256 of the archived text: 35dd73488602d48695ad2d3bdc7eea31cb0566c5d74db92c975f3a5b304b4529
Stable URL of this page: https://metraipolis.com/documento/dc_ca63bf37cb38

How to cite

Tislelizumab-induced myositis antibody-negative myasthenia gravis in patients with urothelial carcinoma: a case report — Europe PMC PMID:42459703 — Europe PMC (en), https://europepmc.org/article/MED/42459703 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ca63bf37cb38 (Metraipolis archive dc_ca63bf37cb38, sha256 35dd73488602d48695ad2d3bdc7eea31cb0566c5d74db92c975f3a5b304b4529)

BibTeX

@misc{dcca63bf37cb38,
  title = {Tislelizumab-induced myositis antibody-negative myasthenia gravis in patients with urothelial carcinoma: a case report — Europe PMC PMID:42459703},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42459703},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ca63bf37cb38; sha256 35dd73488602d48695ad2d3bdc7eea31cb0566c5d74db92c975f3a5b304b4529},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42459703. Agents can read the archived copy with the MCP tool read_document.